ANNOUNCING EMMAC LIFE SCIENCES GROUP AS AN EXCLUSIVE HEALTHCARE PARTNER FOR CANNABIS EUROPA NEW YORK

ANNOUNCING EMMAC LIFE SCIENCES GROUP AS AN EXCLUSIVE HEALTHCARE PARTNER FOR CANNABIS EUROPA NEW YORK

Cannabis Europa is proud to announce EMMAC Life Sciences Group (EMMAC) as the Healthcare partner for our New York conference on November 7th at the Metropolitan club.

EMMAC is Europe’s leading independent cannabis company, bringing together pioneering science and research with cutting-edge cultivation, extraction and production.  With a unique supply and distribution network throughout Europe, EMMAC’s vision is to bring the life-enhancing potential of cannabis to the people who need it. In the past year, EMMAC has built a strong position in Europe in the medical cannabis and wellness markets, with operations in 8 countries. The Company now has an established presence in all aspects of the cannabis supply chain and is well placed to meet the rapidly growing demands of the market, driven by regulatory change and growing consumer demand.

Led by Antonio Costanzo, who previously worked as Head of International Development at the Canadian Nuuvera, EMMAC believes that the growth of the medical cannabis sector must be underpinned by the most robust science. The Company has an active research programme in place, partnering with world-renowned institutions such as Imperial College London and University of Insubria, to further research to support the growth of the medical cannabis industry. The recently expanded collaboration with Imperial College London, has been designed to inform and shape the future of medical cannabis therapies for clinical applications including pain management, cancer therapies and disease-specific trials. 

The strategic partnership with Imperial College puts EMMAC at the very forefront of research in the UK into the medical benefits of cannabis in relation to pain relief. As an industry, all participants must recognise that significant further research is needed to improve the understanding of the medical benefits of cannabis, with basic science and much greater clinical data under-pinning what we consider to be a huge potential market with enormous public health benefits (for patient and clinician). – Antonio Costanzo, CEO of EMMAC

EMMAC is today the largest vertically integrated cannabis company in Europe with operations in eight territories, a cultivation hub in Portugal, 2 EU-GMP certified pharmaceutical labs, in the UK and Spain, and licensed distribution channels across Germany, Italy and the UK. 

Led by seasoned industry executives and with a strong team of 100 staff, including 17 PhDs, EMMAC is establishing itself as a thought leader in the industry, as well as the European leader in the production and supply of medical cannabis, hemp, and other derivative products.

EMMAC is joining Cannabis Europa on November 7th in New York for panels that will address pertinent and efficient questions to drive medical cannabis in Europe forward. EMMAC will share their expertise on how to operate around the nascent European cannabis infrastructure, something that will be key for any business looking to understand and make a move in the European medical cannabis sector. 

“It is an exciting time for the cannabis industry in Europe and we look forward to discussing how EMMAC is capitalising on the opportunities presented by this rapidly evolving market.”  – Antonio Costanzo, CEO of EMMAC

Join us on November 7th at New York’s Metropolitan club to learn about the latest news concerning research, innovation and the production of medicinal cannabis in Europe from those who are at the forefront of this change.